دورية أكاديمية
A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of monotherapy ontuxizumab (MORAb-004) plus best supportive care in patients with chemorefractory metastatic colorectal cancer
| العنوان: | A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of monotherapy ontuxizumab (MORAb-004) plus best supportive care in patients with chemorefractory metastatic colorectal cancer |
|---|---|
| المؤلفون: | Grothey, Axel, Strosberg, Jonathan R., Renfro, Lindsay A., Hurwitz, Herbert I., Marshall, John L., Safran, Howard, Guarino, Michael J., Kim, George P., Hecht, J. R., Weil, Susan C., Heyburn, John, Wang, Wenquan, Schweizer, Charles, O'Shannessy, Daniel J., Diaz, Luis Alberto |
| المصدر: | Medicine Faculty Publications |
| بيانات النشر: | Health Sciences Research Commons |
| سنة النشر: | 2018 |
| المجموعة: | George Washington University: Health Sciences Research Commons (HSRC) |
| الوصف: | © 2017 AACR. Purpose: The purpose of this study was to evaluate the safety and efficacy of ontuxizumab (MORAb-004), a monoclonal antibody that interferes with endosialin (tumor endothelial marker-1) function, in patients with chemorefractory metastatic colorectal cancer and to identify a responsive patient population based on biomarkers. Experimental Design: This was a randomized, double-blind, placebo-controlled, phase II study. Patients were randomly assigned in a 2:1 ratio to receive weekly intravenous ontuxizumab (8 mg/kg) or placebo plus best supportive care until progression or unacceptable toxicity. Tissue and blood biomarkers were evaluated for their ability to identify a patient population that was responsive to ontuxizumab. Results: A total of 126 patients were enrolled. No significant difference between the ontuxizumab and placebo groups was evident for the primary endpoint of progression-free survival (PFS), with a median PFS of 8.1 weeks in each group (HR, 1.13; 95% confidence interval, 0.76-1.67; P = 0.53). There were no significant differences between groups for overall survival (OS) or overall response rate (ORR). The most common treatment-emergent adverse events (TEAEs) in the ontuxizumab group (vs. the placebo group, respectively) were fatigue (53.7% vs. 47.5%), nausea (39.0% vs. 35.0%), decreased appetite (34.1% vs. 27.5%), and constipation (28.0% vs. 32.5%). The most common grade 3/4 TEAE in the ontuxizumab group versus placebo was back pain (11.0% vs. 0%). No single biomarker clearly identified patients responsive to ontuxizumab. Conclusions: No benefit with ontuxizumab monotherapy compared with placebo for clinical response parameters of PFS, OS, or ORR was demonstrated. Ontuxizumab was well tolerated. |
| نوع الوثيقة: | text |
| اللغة: | unknown |
| العلاقة: | https://hsrc.himmelfarb.gwu.edu/smhs_medicine_facpubs/4309Test; https://doi.org/10.1158/1078-0432.CCR-17-1558Test |
| DOI: | 10.1158/1078-0432.CCR-17-1558 |
| الإتاحة: | https://doi.org/10.1158/1078-0432.CCR-17-1558Test https://hsrc.himmelfarb.gwu.edu/smhs_medicine_facpubs/4309Test |
| رقم الانضمام: | edsbas.1F5E76C6 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1158/1078-0432.CCR-17-1558 |
|---|